Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 25, 2018 Filed Oct 29, 2018 21:07 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004308 · primarydocument.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:09 UTC |
STEER RANDOLPH CDirector
|
GrantStock Option (right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004309 · primarydocument.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:09 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004309 · primarydocument.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,226 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:02 UTC |
WIENS HAROLD JDirector
|
GrantStock Option (right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004307 · primarydocument.xml · derivative · entry 2 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:02 UTC |
WIENS HAROLD JDirector
|
GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004307 · primarydocument.xml · nonDerivative · entry 1 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,726 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:00 UTC |
Nusse RoelandDirector
|
GrantStock Option (right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004306 · primarydocument.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 21:00 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004306 · primarydocument.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,226 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:57 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Options (Right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004305 · primarydocument.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:57 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004305 · primarydocument.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:54 UTC |
HIGGINS JOHN LDirector
|
GrantStock Options (Right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004304 · primarydocument.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:54 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004304 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,526 Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:51 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Options (Right to buy) · Derivative | 1,898 | $0.00 Strike: $179.84 | $0.00 |
DisclosureSEC source: 0001562180-18-004303 · primarydocument.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Underlying: Common Stock · 1,898 shares Expires 2028-10-25 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/25/2019) or the date of Bio-Techne 2019 Annual Meeting of Shareholders. Read SEC document |
| October 25, 2018 Filed Oct 29, 2018 20:51 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004303 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,226 Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 21:30 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $61.46 | $0.00 |
DisclosureSEC source: 0001562180-18-003787 · primarydocument.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 21:30 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 5,000 | $188.47 | $942,333.50 |
DisclosureSEC source: 0001562180-18-003787 · primarydocument.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.17 to $188.73, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 21:30 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 5,000 | $61.46 | $307,300.00 |
DisclosureSEC source: 0001562180-18-003787 · primarydocument.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:12 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $61.08 | $0.00 |
DisclosureSEC source: 0000914190-18-000352 · edgar.xml · derivative · entry 12 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:12 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 10,000 | $187.92 | $1,879,173.00 |
DisclosureSEC source: 0000914190-18-000352 · edgar.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.60 to $188.22 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:12 UTC |
HIGGINS JOHN LDirector
|
Exercise / conversionCommon Stock | 10,000 | $61.08 | $610,800.00 |
DisclosureSEC source: 0000914190-18-000352 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2018 Filed Aug 31, 2018 20:39 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 1,338 | $180.50 | $241,509.00 |
DisclosureSEC source: 0001562180-18-003802 · primarydocument.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,176 F1 · balance_after: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to buy) · Derivative | 90,334 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · derivative · entry 10 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,334 Underlying: Common Stock · 90,334 shares Expires 2025-08-08 F6 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to buy) · Derivative | 60,222 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · derivative · entry 9 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,222 Underlying: Common Stock · 60,222 shares Expires 2025-08-08 F7 · derivative.exercise_date: Vests 15,056 shares each on 8/8/2019, 8/8/2020, and 15,055 shares each on 8/8/2021, 8/8/2022. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 16,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · derivative · entry 8 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,918 Underlying: Common Stock · 16,918 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F6 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantCommon Stock | 11,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · nonDerivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,514 F1 · shares: Restrictions lapse as to 3,760 shares on 8/8/19 and 8/8/20 and as to 3,759 shares on 8/8/21 F2 · balance_after: Includes (i) 11,102 shares of restricted stock for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2018 and August 18, 2019; (ii) 14,194 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on each of August 9, 2018 and August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2010 and as to 3,759 shares on August 8, 2021. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantStock Options (Right to buy) · Derivative | 13,550 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 8 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,550 Underlying: Common Stock · 13,550 shares Expires 2025-08-08 F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantStock Options (Right to buy) · Derivative | 18,066 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 7 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,066 Underlying: Common Stock · 18,066 shares Expires 2025-08-08 F5 · derivative.exercise_date: Vests 4,517 shares each on 8/8/2019, 8/8/2020 and 4,516 shares each on 8/8/2021, 8/8/2022. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
GrantRestricted Stock Units · Derivative | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 6 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,537 Underlying: Common Stock · 2,537 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F4 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to buy) · Derivative | 7,339 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,339 Underlying: Common Stock · 7,339 shares Expires 2025-08-08 F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to buy) · Derivative | 9,786 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,786 Underlying: Common Stock · 9,786 shares Expires 2025-08-08 F5 · derivative.exercise_date: Vests 2,447 shares each on 8/8/2019, 8/8/2020, and 2,446 shares each on 8/8/2021, 8/8/2022 Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:26 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 1,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374 Underlying: Common Stock · 1,374 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F4 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to buy) · Derivative | 18,066 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · derivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,066 Underlying: Common Stock · 18,066 shares Expires 2025-08-08 F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to buy) · Derivative | 24,089 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · derivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,089 Underlying: Common Stock · 24,089 shares Expires 2025-08-08 F5 · derivative.exercise_date: Vests 6,023 shares on 8/8/2019, 6,022 shares on each 8/8/2020, 8/8/2021, 8/8/2022 Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:19 UTC |
Hippel JamesChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003542 · primarydocument.xml · derivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,383 Underlying: Common Stock · 3,383 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F4 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:28 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
GrantStock Options (Right to buy) · Derivative | 9,033 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003561 · primarydocument.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,033 Underlying: Common Stock · 9,033 shares Expires 2025-08-08 F2 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:28 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
GrantStock Options (Right to buy) · Derivative | 12,044 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003561 · primarydocument.xml · derivative · entry 2 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,044 Underlying: Common Stock · 12,044 shares Expires 2025-08-08 F3 · derivative.exercise_date: Vests 3,011 shares each on 8/8/2019, 8/8/2020, 8/8/2021, 8/8/2022 Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:28 UTC |
Kelderman KimPresident, Diagnostics & Genom
|
GrantRestricted Stock Units · Derivative | 1,691 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003561 · primarydocument.xml · derivative · entry 1 Kelderman Kim · CIK 0001739054 · President, Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691 Underlying: Common Stock · 1,691 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:18 UTC |
Dinarello Charles ADirector
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $63.06 | $0.00 |
DisclosureSEC source: 0001562180-18-003560 · primarydocument.xml · derivative · entry 3 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:18 UTC |
Dinarello Charles ADirector
|
SaleCommon Stock | 5,000 | $176.94 | $884,675.00 |
DisclosureSEC source: 0001562180-18-003560 · primarydocument.xml · nonDerivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,212 Read SEC document |
| August 08, 2018 Filed Aug 10, 2018 20:18 UTC |
Dinarello Charles ADirector
|
Exercise / conversionCommon Stock | 5,000 | $63.03 | $315,150.00 |
DisclosureSEC source: 0001562180-18-003560 · primarydocument.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Disposition to issuerStock Options (Right to buy) · Derivative | 23,929 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · derivative · entry 7 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,346 Underlying: Common Stock · 23,929 shares Expires 2022-08-07 F5 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 95,346 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Disposition to issuerRestricted Stock Units · Derivative | 3,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · derivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,467 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 13,816 performance RSUs. The remainder of the performance RSUs were forfeited. F4 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 13,816 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 13,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,467 Underlying: Common Stock · 13,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 13,816 performance RSUs. The remainder of the performance RSUs were forfeited. F4 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 13,816 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 1,752 | $180.14 | $315,605.28 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,235 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 6,301 | $180.14 | $1,135,062.14 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,987 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 13,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003545 · primarydocument.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Disposition to issuerStock Options (Right to buy) · Derivative | 1,881 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 5 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,494 Underlying: Common Stock · 1,881 shares Expires 2022-08-07 F3 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 7,494 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Disposition to issuerRestricted Stock Units · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 4 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 301 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Exercise / conversionRestricted Stock Units · Derivative | 1,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · derivative · entry 3 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301 Underlying: Common Stock · 1,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Tax withholdingCommon Stock | 348 | $180.14 | $62,688.72 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,117 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:29 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Exercise / conversionCommon Stock | 1,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003544 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.